EuroPCR 2024 | DOCTORS-LM Trial: CTO Optimizes Stent Outcomes in Left Main Disease?

The aim of this randomized open study was to determine whether CTO guided left main percutaneous coronary intervention (PCI) is superior to fluoroscopy guided PCI, using fractional flow reserve (FFR) after stenting.

EuroPCR 2024

The secondary outcomes were procedural success (successful implantation, malposition, edge dissection or stent collapse) and major adverse cardiovascular events (MACE) at one year.

The study included 197 non-ST elevation acute coronary syndrome (NST ACS) patients with unstable angina, stable angina or silent ischemia, with significant angiographic or FFR left main lesion (%DS ≥50% and ≤0.80 respectively)and ≤ 22 Syntax score.

CTO patients were assessed prior and post PCI, while the angiography only patients received fluoroscopy. Both groups had a final assessment and FFR was carried out after 12 months. 

As to the primary FFR outcomes, there were no significant differences between the groups (0.894 ± 0.049 vs 0.889 ± 0.056; P=0.5237). However, when looking at procedural success, a significant difference was observed in favor of CTO (58.9% vs 34.4%; P=0.0009), especially as regards sub-expansion optimization (P=0.08), malposition (P=0.0005) and stent collapse (P=0.0045). The difference in MACE was smaller and with no statistical significance mainly due to target vessel failure (TVF).

Read also: EuroPCR 2024 | Prognostic Value of MRR in STEMI: Group Analysis of Individual Patients.

Therefore, the authors concluded that, compared against conventional PCI, the use of CTO did not show significant differences in functional outcomes (FFR). However, it did show better procedural success and lower incidence of new revascularization. 

Dr. Omar Tupayachi

Dr. Omar Tupayachi.
Member of the Editorial Board of SOLACI.org.

Reference: Presented by Nicolas Meneveau at Late-Breaking Clinical Trials, EuroPCR 2024, May 14-17, Paris, France.


Subscribe to our weekly newsletter

Get the latest scientific articles on interventional cardiology

More articles by this author

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

AHA 2024 – BPROAD

Hypertension (elevated blood pressure, BP) is the most common comorbidity among diabetic patients and has been associated with higher cardiovascular risk, though as a...

Coronary Artery Disease in Aortic Stenosis: CABG + SAVR vs. TAVR + PCI: Data from Spanish Centers

Multiple randomized studies have shown comparable or superior efficacy of transcatheter aortic valve replacement (TAVR) vs. coronary artery bypass graft (CABG).  However, many of...

Evolution of Small Balloon-Expandable Valves

Small aortic rings (20 mm) have posed a significant challenge for both surgery and transcatheter aortic valve implantation (TAVI) due to their association with an...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Related Articles

SOLACI Sessionsspot_img

Recent Articles

AHA 2024 | VANISH2 Trial

Cardiac defibrillator implants (CDIs) have been shown to improve survival in patients with ischemic cardiomyopathy and ventricular tachycardia (VT). However, approximately one third of...

AHA 2024 | SUMMIT

It has been previously shown that the pharmacological treatment of obesity (semaglutide) can reduce cardiovascular events in patients with cardiac failure (CF) and preserved...

AHA 2024 – BPROAD

Hypertension (elevated blood pressure, BP) is the most common comorbidity among diabetic patients and has been associated with higher cardiovascular risk, though as a...